AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Bogdanoff who wrote (394)	8/16/1997 12:05:00 PM
From: tonyt	of 2173

Of course FDA approval (not scheduled for application until the end of next year) will be needed for Amylin to succeed, but even then, who's to say that a competing company might have a better product? I disagree with your opinion that the results were not compeling as the press release stated that for type 1 diabetes pramlintide's effect on lowering glucose and improving weight and cholesterol profiles were statistically significant and clinically meaningful. I'm not qualified to interpret the data, but the statements 'statistically significant and clinically meaningful' seem compeling to me. As far as Type 2, the results, while not positive, were encouraging. --Tony

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next